HF
MLTX icon

HRT Financial’s MoonLake Immunotherapeutics MLTX Stock Holding History

HRT Financial’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-22,300
Closed -$415K – 4913
2026
Q1 		$415K Buy
+22,300
New +$369K ﹤0.01% 2661

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

HRT Financial's MLTX Position: Q2 2026 in Review

HRT Financial increased its MoonLake Immunotherapeutics (MLTX) stake by 39% in Q2 2026, buying an estimated $3.47M and bringing the position to 679,244 shares worth $13.2M. The position accounts for 0.02% of the portfolio, ranked #649.

HRT Financial first reported a position in MLTX in Q4 2020 and has held it in 12 quarters since. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • HRT Financial held 679,244 shares of MoonLake Immunotherapeutics worth $13.2M as of Q2 2026.
  • HRT Financial bought 191,661 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $3.47M.
  • MoonLake Immunotherapeutics made up 0.02% of HRT Financial's portfolio in Q2 2026, its #649 holding.
  • HRT Financial first reported a position in MoonLake Immunotherapeutics in Q4 2020 and has held it in 12 quarters since.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.